Search Results 221-230 of 12322 for Multiple myeloma red flag

1. Thalidomide (oral route) - Side effects & dosage - Mayo Clinic

   It also interferes with the growth of multiple myeloma cells, which are eventually destroyed in the body. ... red spots on your skin. Be careful when using a ...

2. Safety And Efficacy Of Bb2121 (Ide-cel) Combinations In Multiple Myeloma - Mayo Clinic

   The purpose of this study is to determine the safety and effectiveness of bb2121 (Ide-Cel) combinations in subjects with relapsed/refractory multiple myeloma.

3. A Study Comparing Anitocabtagene Autoleucel To Standard Of Care Therapy In Participants With Relapsed/ Refractory Multiple Myeloma (IMMagine-3) - Mayo Clinic

   Clinical Trials · A Study Comparing Anitocabtagene Autoleucel To Standard Of Care Therapy In Participants With Relapsed/ Refractory Multiple Myeloma (IMMagine-3).

4. A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma - Mayo Clinic

   ... Multiple Myeloma. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information. Overview. Tab ...

5. Mayo Clinic Q&A - Dr. Yi LIn - Multiple myeloma

   In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out the healthy blood cells. Immunotherapy, which uses the body's immune ...

6. Comparison Of MRI In The Evaluation Of Multiple Myeloma - Mayo Clinic

   The purpose of this study is to compare the utility of whole body MRI (WBMRI) with diffusion-weighted imaging (DWI) and simultaneous 18F-FDG PET/MRI with time ...

7. Addition Of Daratumumab To Combination Of Bortezomib And Dexamethasone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

   Addition Of Daratumumab To Combination Of Bortezomib And Dexamethasone In Participants With Relapsed Or Refractory Multiple Myeloma ... multiple myeloma.

8. Mayo Clinic researchers identify gene types driving racial disparities in myeloma

   Share this: Share to facebook · Share to twitter · Share to linkedin · Share to email Print. Bone marrow aspirate cytology of multiple myeloma. ROCHESTER Minn ...

9. A Study To Evaluate Subcutaneous Daratumumab In Combination With Standard Multiple Myeloma Treatment Regimens - Mayo Clinic

   The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) ...

10. An Efficacy And Safety Study Of Daratumumab In Patients With Multiple Myeloma Who Have Received At Least 3 Prior Lines Of Therapy (Including A Proteasome Inhibitor [PI] And Immunomodulatory Drug [IMiD]) Or Are Double Refractory To A PI And An IMiD - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at ...